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Molecular genetic analysis of hereditary leiomyomatosis and renal cell cancer (HLRCC) unexpect-
edly revealed germline defects in the gene encoding the Krebs cycle enzyme fumarate hydratase 
(FH), stimulating great interest in the underlying mechanism of oncogenesis. It has been proposed 
that the associated accumulation of fumarate competitively inhibits the 2-oxoglutarate-dependent 
dioxygenases that regulate hypoxia-inducible factor (HIF), thus activating oncogenic hypoxia path-
ways. In this issue of Cancer Cell, Pollard and colleagues describe a genetic mouse model of FH 
deficiency that recapitulates aspects of the human disease, including HIF activation and renal cysts, 
enabling further insights into this unusual cancer syndrome.The association of tumor hypoxia 
with aggressive cancer phenotypes 
is well established, with parenchymal 
hypoxia within solid tumors predict-
ing not only resistance to treatment 
but also adverse natural history. Nev-
ertheless, precise understanding of 
the mechanisms underlying these 
associations is lacking, and the dis-
tinction of cause and effect remains 
problematic. Thus, the involvement of 
genetic defects in hypoxia signaling 
pathways in predisposition to can-
cer is of great interest. Considerable 
attention has been focused on defin-
ing the role of HIF in von Hippel-Lin-
dau (VHL)-associated cancer, where 
inactivation of the VHL ubiquitin E3 
ligase blocks proteolytic degrada-
tion of HIF and upregulates HIF tar-
get genes (Kaelin, 2002). Against this 
background, reports linking heredi-
tary cancer syndromes to defects 
in Krebs cycle enzymes that also 
appear to perturb HIF degradation, 
but by different mechanisms, have 
attracted widespread attention (Got-
tlieb and Tomlinson, 2005).
In mammalian cells, hypoxia-
induced changes in gene expression 
extend to several hundred transcripts, 
the majority of which respond directly 
or indirectly to the α/β heterodimeric 
transcription factor HIF. The oxygen-
sensitive signal is generated by enzy-
matic hydroxylations of specific prolyl 
and asparaginyl residues within HIFα subunits (HIF1α, HIF2α, and HIF3α) 
that promote proteolytic destruc-
tion and transcriptional inactivation 
of HIF in the presence of oxygen. 
These hydroxylations are catalyzed 
by a series of nonheme Fe (II) and 
2-oxoglutarate-dependent dioxygen-
ases that split molecular oxygen and 
couple the hydroxylation of HIFα to 
the oxidative decarboxylation of the 
Krebs cycle intermediate 2-oxoglu-
tarate (Schofield and Ratcliffe, 2004). 
These findings suggested that, in 
addition to oxygen dependence, 
the system might be perturbed by 
changes in intermediary metabolism Cancer Ceaffecting Krebs cycle metabolites, 
providing an appealing link between 
hypoxic and metabolic signals.
Two quite distinct hereditary cancer 
syndromes have been shown to be 
caused by mutations in genes encod-
ing Krebs cycle enzymes. Hereditary 
pheochromocytoma and paragan-
glioma are associated with mutation 
in succinate dehydrogenase (sdh) 
subunits B, C, and D, while HLRCC, 
a syndrome characterized by multiple 
benign skin and uterine leimyomata, 
occasional leiomyosarcoma, and in 
some families, aggressive renal cell 
carcinoma, is associated with muta-Figure 1. Postulated Oncogenic Pathways in Cells Deficient in Fumarate Hydratase 
or Succinate Dehydrogenase
Accumulation of the Krebs cycle intermediates fumarate and succinate is proposed to inhibit HIF 
hydroxylases or other 2-oxoglutarate-dependent dioxygenases, leading to upregulation of HIF or 
other oncogenic substrates.ll 11, April 2007 ©2007 Elsevier Inc. 303
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2005). In each case, associated 
tumors manifest upregulation of HIF, 
and based on the established role of 
particular Krebs cycle intermediates 
(including fumarate and succinate) in 
inhibiting other 2-oxoglutarate-depen-
dent dioxygenases (procollagen prolyl 
and lysyl hydroxylases), it was pro-
posed that upregulation of HIF might 
be due to inhibition of the HIF hydrox-
ylases by Krebs cycle intermediates, 
and that activation of the HIF pathway 
might be the cause of the tumor pre-
disposition (Figure 1).
If true, this would have interesting 
general implications. First, it raises 
the possibility that other circum-
stances in which intermediary metab-
olism is perturbed (either in neoplasia 
or nonneoplastic conditions) might 
modulate HIF signaling. Second, it 
adds to accumulating evidence that 
the generally observed associa-
tions between activation of the HIF 
pathways and tumor growth might, 
in some circumstances, be causal. 
However, the hypothesized model 
is by no means proven, and each of 
the links in the proposed sequence of 
events requires careful consideration. 
The mouse model of fh inactivation 
generated by Pollard and colleagues 
should therefore be of substantial 
utility (Pollard et al., 2007). Moreover, 
using biallelic genetic inactivation 
in embryonic stem cells, Pollard et 
al. provide secure evidence that fh 
inactivation does indeed upregulate 
HIFα, consistent with data reported 
previously using pharmacological 
inhibition of FH and fh-directed siR-
NAs (Isaacs et al., 2005; Pollard et 
al., 2007). But is the proposed mech-
anism of HIF activation by fumarate 
accumulation correct?
Recent in vitro data confirm that 
fumarate is an effective inhibitor of 
the HIF prolyl hydroxylases and that 
inhibition is competitive with 2-oxo-
glutarate, with IC50 values reported at 
6.6 µM and 80 µM in different assays 
(Isaacs et al., 2005; Koivunen et al., 
2007). Studies of tumor extracts from 
FH-associated myomata reveal large 
increases in fumarate—to concentra-
tions well in excess of these levels 
(Pollard et al., 2005). Thus, notwith-304 Cancer Cell 11, April 2007 ©2007 Elstanding uncertainties arising from 
cellular compartmentalization (the 
Krebs cycle reactions takes place 
within the mitochondrion, whereas 
the most likely sites of HIF hydrox-
ylation are within the cytosol and 
the nucleus), kinetic measurements 
are consistent with fh inactivation 
impairing HIF hydroxylation through 
fumarate accumulation. Succinate 
accumulation in SDH-associated 
tumors is less clearly in excess of the 
reported IC50 for HIF prolyl hydroxy-
lases (Koivunen et al., 2007; Pollard 
et al., 2005). However, reversal of 
HIFα accumulation in SDH-deficient 
cells following application of esteri-
fied (cell-permeant) 2-oxoglutarate 
strongly suggests that a similar pro-
cess of competitive inhibition of HIF 
hydroxylases is taking place (Mack-
enzie et al., 2007). Thus, it seems 
likely that severe dysregulation of the 
Krebs cycle can upregulate hypoxia 
signaling in these rare disorders. 
Might more subtle metabolic dysreg-
ulation also have significant effects in 
more commonly encountered situa-
tions? Demographic observations of 
altitude dependence of paragangli-
oma incidence in families bearing sdh 
mutations suggests an interaction 
with hypoxia. Conceivably, changes 
in intermediary metabolism that affect 
the entry to the Krebs cycle via acetyl 
CoA, or via anaplerotic pathways that 
allow metabolite entry at other points 
in the cycle, might affect the levels of 
relevant metabolites in a manner that 
modulates hypoxia signaling. More-
over, correction of HIF upregulation 
in SDH-deficient cells by exogenous 
2-oxoglutarate suggests that thera-
peutic correction might be feasible 
(Mackenzie et al., 2007). The mouse 
model of fh deficiency reported by 
Pollard and colleagues should now 
enable testing of these interesting 
possibilities (Pollard et al., 2007).
What of the link between activa-
tion of HIF and cancer? Pollard et 
al. describe proliferation of the renal 
epithelium and renal cysts following 
inactivation of fh (Pollard et al., 2007). 
This pathology was associated with 
life-limiting polyuric renal failure. 
Since in some (but by no means all) 
disease settings renal cysts are con-sevier Inc.sidered to be precursors of renal cell 
cancer, it is possible that, had the 
animals survived longer, renal cancer 
would have developed. The situation 
is thus similar to RCC-associated 
VHL disease, where inactivation of 
vhl in mouse renal epithelial results 
in proliferation and cystic change but 
not overt RCC. In the mouse model 
of VHL disease, renal cyst develop-
ment can be corrected by inactiva-
tion of HIF1β, though interestingly 
not HIF1α (Rankin et al., 2006), and 
in experimental tumors derived from 
human RCC, genetic manipulation 
strongly implicates a causal role for 
HIF2α in promoting growth (Kaelin, 
2002). Thus, it is tempting to suggest 
a similar mode of oncogenesis in VHL 
and HLRCC disease, with HIF activa-
tion as the common factor. However, 
there are differences. In VHL-asso-
ciated RCC, upregulation of the HIF 
target gene carbonic anhydrase 9 is a 
consistent feature, and attention has 
focused on upregulation of the HIF2α 
targets TGFα and Cyclin D1 as likely 
contributors to cellular proliferation 
(Kaelin, 2002). In the report by Pollard 
et al., cyclin D1 expression was not 
measured, and renal cysts expressed 
neither CA9 not TGFα (Pollard et al., 
2007). Thus, if HIF activation does 
underlie cyst development in both 
VHL disease and HLRCC the tran-
scriptional targets that mediate the 
changes may well be different. Fur-
thermore, the proposed mechanism 
does not explain the tissue-specific 
differences in tumor predisposition 
observed in VHL-, FH-, and SDH-
associated cancer syndromes.
Thus, though fh inactivation can 
upregulate HIF, the causal role of HIF in 
renal cyst development (and other man-
ifestations of FH and SDH deficiency) is 
less clearly established. Combining FH- 
and HIFα-defective alleles in the new 
mouse model should now permit this 
to be tested. Meantime, it is important 
to recognize first, that the HIF hydroxy-
lases may have other oncogenic sub-
strates in these diseases (Lee et al., 
2005), and second, that fumarate or 
succinate accumulation might (in par-
allel with HIF hydroxylation) inhibit any 
of several dozen known or predicted 
2-oxoglutarate-dependent dioxygen-
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(Schofield and Ratcliffe, 2004). Other 
2-oxoglutarate-dependent dioxygen-
ases that have credible roles in cancer 
biology include those with long-estab-
lished functions in extracellular matrix 
formation, such as procollagen prolyl 
and lysyl hydroxylases, and those with 
recently established functions in his-
tone demethylation (Shi and Whetstine, 
2007). Thus, it remains conceivable that 
HIF activation is a marker rather than 
the cause of oncogenic predisposition 
and/or that different types of tumor 
predisposition reflect effects on differ-
ent enzyme/substrate systems. Either 
way, the new findings open a range of 
possible insights into the association of 
hypoxia and cancer progression.Sarcomas comprise a diverse 
group of malignant tumors of mes-
enchymal origin, arising in connec-
tive tissues such as fat, muscle, 
fibrous tissue, and bone (Helman 
and Meltzer, 2003). These tumors 
are relatively rare, with an annual 
incidence of seven to eight per 
100,000. They account for less than 
1% of all malignancies overall, but 
about 15% of malignancies in chil-
dren. Sarcomas have historically 
been classified based on their site 
of origin, morphology, and immuno-
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events provide a point of departure 
for sarcoma researchers. Impor-
tantly, the translocations are likely 
to reveal biological mechanisms 
whose importance transcends the 
rarity of these diseases. However, 
despite the opportunities provided 
by the discovery of sarcoma trans-
locations, biological understanding 
of many sarcomas remains limited. 
The rarity of sarcomas and their 
clinical heterogeneity, even within 
a single histologic classification, 
present the greatest obstacles. 
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